glp-1/gcgr dual agonist LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Structural basis for the therapeutic

Autophagy regulates the degeneration of the auditory cortex through the AMPK-mTOR-ULK1 signaling pathway

Sato T et al

Do tanning nasals or injections work

Pemvidutide, developed by Altimmune, is a GLP-1/glucagon dual agonist that has completed Phase 2 trials for obesity (MOMENTUM, 15.6% weight loss at 48 weeks) and MASH (IMPACT, up to 59.1% MASH resolution)

Several commenters supported reimbursement methodology outlined in Senate Bill 2561 (Skin Substitute Access and Payment Reform Act of 2025), which would establish rates based on Q4 2023 ASP data volume-weighted according to actual utilization in both the professional and hospital outpatient settings

Since then, few patients discontinued setmelanotide due to objections over pigment changes